Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, has announced its audited financial results for the fourth quarter and full financial year ending 31st March 2026. The company reported a robust performance with significant year-on-year growth across various financial metrics.
For the fourth quarter of FY26, Senores Pharmaceuticals recorded a total income of ₹190 crore, marking a 58% increase compared to the same period last year. The company’s EBITDA for Q4FY26 stood at ₹62 crore, reflecting a 144% year-on-year growth. The profit after tax (PAT) also saw a substantial rise, reaching ₹37 crore, which is a 105% increase from the previous year.
In the full financial year FY26, the company achieved a total income of ₹664 crore, up by 62% from FY25. The EBITDA for the year was reported at ₹200 crore, showing a 96% increase, while the PAT reached ₹122 crore, marking a 108% growth year-on-year.
Segment-wise, the regulated markets contributed ₹117.8 crore in Q4FY26, an 83% increase from the previous year, and ₹427.4 crore for the full year, a 74.6% rise. Emerging markets generated ₹45.9 crore in Q4FY26, up 25.8% from the previous year, and ₹145 crore for FY26, a 19.7% increase. The branded generics segment saw remarkable growth, with revenue increasing by 132.4% in Q4FY26 to ₹9.4 crore and by 385.3% for the full year to ₹40 crore.
Senores Pharmaceuticals also highlighted its strategic acquisitions and joint ventures during FY26. The company acquired a 51% membership interest in Zoraya Pharmaceuticals, LLC, and completed the first phase of a 75% stake acquisition in Apnar Pharmaceuticals, with plans to acquire the remaining 25% by Q2FY27. Additionally, Senores entered into a 70% joint venture, Amerisyn, in the U.S. to supply pharmaceuticals to federal and defense sectors.
Swapnil Shah, Managing Director of Senores Pharmaceuticals, commented on the performance, stating that the company delivered robust results across segments despite an uncertain operating environment. He emphasised the company’s strong pipeline of products and expanded manufacturing capacities as key drivers for sustained growth.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).